Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used ...

The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

Once seen as an alternative option, the ketamine nasal spray Spravato is now a mainstream prescription for treatment-resistant depression, often recommended in standard guides, he added.

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...